Targets in Heterocyclic Systems

Total Page:16

File Type:pdf, Size:1020Kb

Targets in Heterocyclic Systems Italian Society of Chemistry Division of Organic Chemistry Division of Medicinal Chemistry Division of Mass Spectrometry TARGETS IN HETEROCYCLIC SYSTEMS Chemistry and Properties Volume 17 (2013) Reviews and Accounts on Heterocyclic Chemistry http://www.soc.chim.it/it/libriecollane/target_hs Editors Prof. Orazio A. Attanasi University of Urbino “Carlo Bo”, Urbino, Italy and Prof. Domenico Spinelli University of Bologna, Bologna, Italy Published by: Società Chimica Italiana Viale Liegi, 48 00198 Roma Italy ___________________________________________________________________________ Copyright © 2013 Società Chimica Italiana All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means (electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise) without permission in writing from the publishers. A person may photocopy an article for personal use. Volume 1 (1997) First edition 1997 ISBN 88-86208-24-3 Second edition 1999 ISBN 88-86208-24-3 Volume 2 (1998) First edition 1999 ISBN 88-86208-11-1 Volume 3 (1999) First edition 2000 ISBN 88-86208-13-8 Volume 4 (2000) First edition 2001 ISBN 88-86208-16-2 Volume 5 (2001) First edition 2002 ISBN 88-86208-19-7 Volume 6 (2002) First edition 2003 ISBN 88-86208-23-5 Volume 7 (2003) First edition 2004 ISBN 88-86208-28-6 ISSN 1724-9449 Volume 8 (2004) First edition 2005 ISBN 88 86208-29-4 ISSN 1724-9449 Volume 9 (2005) First edition 2006 ISBN 88 86208-31-6 ISSN 1724-9449 Volume 10 (2006) First edition 2007 ISBN 978-88-86208-51-2 ISSN 1724-9449 Volume 11 (2007) First edition 2008 ISBN 978-88-86208-52-9 ISSN 1724-9449 Volume 12 (2008) First edition 2009 ISBN 978-88-86208-56-7 ISSN 1724-9449 Volume 13 (2009) First edition 2010 ISBN 978-88-86208-62-8 ISSN 1724-9449 Volume 14 (2010) First edition 2011 ISBN 978-88-86208-67-3 ISSN 1724-9449 Volume 15 (2011) First edition 2012 ISBN 978-88-86208-70-3 ISSN 1724-9449 Volume 16 (2012) First edition 2013 ISBN 978-88-86208-72-7 ISSN 1724-9449 Volume 17 (2013) First edition 2014 ISBN 978-88-86208-75-8 ISSN 1724-9449 Printed and bound in Italy by: Arti Grafiche Editoriali s.r.l. Via S. Donato, 148/C 61029 Urbino (Pesaro-Urbino) Italy June 2014 Editorial Advisory Board Members Prof. Jan Bergman Prof. Gianluca Giorgi Karolinska Institute University of Siena Huddinge, Sweden Siena, Italy Prof. Robert K. Boeckman Jr. Prof. Lucedio Greci University of Rochester University of Ancona Rochester, USA Ancona, Italy Prof. José A. S. Cavaleiro Prof. Laurence M. Harwood University of Aveiro University of Reading Aveiro, Portugal Reading, UK Prof. Leopoldo Ceraulo Prof. Steven V. Ley University of Palermo University of Cambridge Palermo, Italy Cambridge, UK Prof. Girolamo Cirrincione Prof. Pedro Merino University of Palermo University of Zaragoza Palermo, Italy Zaragoza, Spain Prof. Janine Cossy Prof. Renato Noto ESPCI University of Palermo Paris, France Palermo, Italy Dr. Daniele Donati Prof. Giovanni Sindona Glaxo Wellcome University of Calabria Verona, Italy Arcavacata di Rende, Italy Prof. José Elguero Prof. Branko Stanovnik CSIC University of Ljubljana Madrid, Spain Ljubljana, Slovenia Prof. Dieter Enders Prof. Richard J. K. Taylor RWTH University of York Aachen, Germany York, UK Prof. Leon Ghosez Prof. Eric J. Thomas Catholic University of Louvain University of Manchester Louvain la Neuve, Belgium Manchester, UK Preface Heterocyclic derivatives are important in organic chemistry as products (including natural) and/or useful tools in the construction of more complicated molecular entities. Their utilization in polymeric, medicinal and agricultural chemistry is widely documented. Dyestuff, electronic, and tanning structures, as well as life molecules frequently involve heterocyclic rings that play an important role in several chemical and biochemical processes. Volume 17 (2013) keeps the international standard of TARGETS IN HETEROCYCLIC SYSTEMS – Chemistry and Properties (THS) series and contains eight chapters, covering the synthesis, reactivity, and activity (including medicinal) of different heterorings. Authors from Canada, France, Italy, Spain, and Ukraine are present in this book. As yet, THS Volumes 1-17 published 229 reviews by 646 authors from 30 different countries for a total of about 7.000 pages. Comprehensive Reviews reporting the overall state of the art on wide fields as well as personal Accounts highlighting significative advances by research groups dealing with their specific themes have been solicited from leading Authors. The submission of articles having the above-mentioned aims and concerning highly specialistic topics is strongly urged. The publication of Chapters in THS is free of charge. Firstly a brief layout of the contribution proposed, and then the subsequent manuscript, may be forwarded either to a Member of the Editorial Board or to one of the Editors. The Authors, who contributed most competently to the realization of this Volume, and the Referees, who cooperated unselfishly (often with great patience) spending valuable attention and time in the review of the manuscripts, are gratefully acknowledged. The Editors thank very much Dr. Lucia De Crescentini for her precious help in the editorial revision of the book. Orazio A. Attanasi and Domenico Spinelli Editors Table of Contents (for the contents of Volumes 1–16 please visit: http://www.soc.chim.it) Recent advances in pyrimidine derivatives as luminescent, photovoltaic 1 and non-linear optical materials Sylvain Achelle and Christine Baudequin 1. Introduction 2. Pyrimidines 2.1. Arylpyrimidines and arylethynylpyrimidines 2.2. Arylvinylpyrimidines and aryliminepyrimidines 2.3. Organometallic and coordinated pyrimidine derivatives 3. Quinazolines 4. Pyrrolo[2,3-d]pyrimidines 5. Other fused pyrimidines 6. Conclusions References A unified strategy for the synthesis of bridged indole alkaloids and their close analogues 35 M.-Lluïsa Bennasar 1. Introduction 2. Construction of the ervitsine ring system 3. First total synthesis of apparicine 3.1. Initial studies 3.2. Completion of the total synthesis 4. Synthesis of cleavamine-type indole alkaloids and their 5-nor derivatives 4.1. Construction of the 5-nor cleavamine skeleton 4.2. Total synthesis of cleavamines 5. Conclusion Acknowledgments References Recent advances in the synthesis of selected indolizidine and quinolizidine alkaloids 57 Sunil V. Pansare and Rakesh G. Thorat 1. Introduction 2. Scope and organization of the review 3. Synthetic strategies for selected indolizidine and quinolizidine alkaloids 3.1. Ring formation via nucleophilic displacement or addition reactions 3.1.1. Nitrogen-carbon cyclizations with preformed azacycles as starting materials 3.1.2. Nitrogen-carbon cyclizations with open chain precursors 3.1.3. Carbon-carbon cyclizations with preformed azacycles as starting materials I 3.1.4. Carbon-carbon cyclizations via azacyclic intermediates 3.2. Syntheses employing ring closing metathesis as a key transformation 3.3. Asymmetric cycloaddition-based strategies 3.4. Iminium ion-based approaches 3.5. Syntheses involving organocatalysis 4. Closing remarks Acknowledgments References Thiazolo[5,4-d]thiazole-based compounds: emerging targets in materials science, 87 organic electronics and photovoltaics Lorenzo Zani, Massimo Calamante, Alessandro Mordini and Gianna Reginato 1. Introduction 2. Synthesis, elaboration and characterization of thiazolo[5,4-d]thiazoles and related materials 2.1. Synthesis and functionalization of thiazolo[5,4-d]thiazoles 2.2. Thiazolothiazole-based polymers 2.3. Structural, photophysical and spectroscopic properties 3. Applications of thiazolo[5,4-d]thiazole-based materials 3.1. Biological activity 3.2. Preparation of metal complexes and crystal engineering 3.3. Non-linear optics and fluorescent sensors/emitters 3.4. Organic light-emitting diodes 3.5. Organic field-effect transistors 3.6. Organic and polymeric solar cells 3.7. Dye-sensitized solar cells 4. Conclusions Acknowledgments References Synthesis and photophysical properties of the green fluorescent 125 protein chromophore and analogues David Martínez-López and Diego Sampedro 1. Introduction 2. Synthesis of GFP chromophore analogues 2.1. Synthesis of oxazolones 2.2. Synthesis of imidazolinones 2.3. Synthesis of other derivatives 3. Photophysical properties of GFP and GFP derivatives 3.1. Absorption 3.1.1. Oxazolones II 3.1.2. Imidazolinones 3.2. Fluorescence 3.2.1. Oxazolones 3.2.2. Imidazolinones 3.3. Photoisomerisation 3.4. Photophysical properties of other derivatives 4. Applications 5. Conclusions Acknowledgments References Synthesis, chemical and biological properties of trifluoromethylated 147 pyrimidin-2-ones(thiones) and their fused analogues Veronika M. Shoba, Viktor M. Tkachuk, Volodymyr A. Sukach and Mykhailo V. Vovk 1. Introduction 2. Synthesis of trifluoromethylated pyrimidin-2-ones(thiones) 2.1. Biginelli reaction 2.2. [NCN]+[CCC] cyclization 2.3. [CCCN]+[CN] cyclization 2.4. [CNC]+[NCC] cyclization 3. Chemical properties of trifluoromethylated pyrimidin-2-ones(thiones) 3.1. Nucleophilic addition reactions 3.2. Photochemical reactions and processes involving free radicals 4. Biological properties of trifluoromethylated pyrimidin-2-ones(thiones) 5. Conclusions References Biocatalysis applied to the synthesis of valuable triazole-contaning derivatives 176 Aníbal Cuetos, Fabricio R. Bisogno and Iván Lavandera 1. Introduction 2. Biocatalytic approaches over triazole-containing derivatives 2.1. 1,2,3-Triazoles 2.1.1. Using hydrolases
Recommended publications
  • Author Index Volumes 201–244
    Author Index Volumes 201–244 Author Index Vols. 26–50 see Vol. 50 Author Index Vols. 51–100 see Vol. 100 Author Index Vols. 101–150 see Vol. 150 Author Index Vols. 151–200 see Vol. 200 The volume numbers are printed in italics Achilefu S, Dorshow RB (2002) Dynamic and Continuous Monitoring of Renal and Hepatic Functions with Exogenous Markers. 222: 31–72 Albert M, see Dax K (2001) 215: 193–275 Albrecht M (2005) Supramolecular Templating in the Formation of Helicates. 248: 105–139 Ando T, Inomata S-I, Yamamoto M (2004) Lepidopteran Sex Pheromones. 239: 51–96 Angyal SJ (2001) The Lobry de Bruyn-Alberda van Ekenstein Transformation and Related Reactions. 215: 1–14 Antzutkin ON, see Ivanov AV (2005) 246: 271–337 Anupõld T, see Samoson A (2005) 246: 15–31 Armentrout PB (2003) Threshold Collision-Induced Dissociations for the Determination of Accurate Gas-Phase Binding Energies and Reaction Barriers. 225: 227–256 Astruc D, Blais J-C, Cloutet E, Djakovitch L, Rigaut S, Ruiz J, Sartor V,Valério C (2000) The First Organometallic Dendrimers: Design and Redox Functions. 210: 229–259 Augé J, see Lubineau A (1999) 206: 1–39 Baars MWPL, Meijer EW (2000) Host-Guest Chemistry of Dendritic Molecules. 210: 131– 182 Balazs G, Johnson BP, Scheer M (2003) Complexes with a Metal-Phosphorus Triple Bond. 232: 1–23 Balbo Block MA, Kaiser C, Khan A, Hecht S (2005) Discrete Organic Nanotubes Based on a Combination of Covalent and Non-Covalent Approaches. 245: 89–150 Balczewski P,see Mikoloajczyk M (2003) 223: 161–214 Ballauff M (2001) Structure of Dendrimers in Dilute Solution.
    [Show full text]
  • Lonsurf (Trifluridine/Tipiracil) Were Bone Marrow Suppression and Gastrointestinal Toxicity
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrLONSURF® trifluridine and tipiracil tablet 15 mg trifluridine/ 6.14 mg tipiracil (as tipiracil hydrochloride) 20 mg trifluridine / 8.19 mg tipiracil (as tipiracil hydrochloride) Antineoplastic Agent Thymidine phosphorylase inhibitor/nucleoside metabolic inhibitor Taiho Pharma Canada, Inc. Date of Initial Approval: 2010 Winston Park Drive, Suite 503 January 23, 2018 Oakville, Ontario L6H 5R7 Canada Submission Control No: 205852 Page 1 of 35 RECENT MAJOR LABEL CHANGES Not Applicable TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ......................................................................................2 TABLE OF CONTENTS ..............................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION ............................................................4 1 INDICATIONS....................................................................................................................4 1.1 Pediatrics ....................................................................................................................4 1.2 Geriatrics ....................................................................................................................4 2 CONTRAINDICATIONS ..................................................................................................4 3 DOSAGE AND ADMINISTRATION ...............................................................................4 3.1 Dosing Considerations
    [Show full text]
  • These Highlights Do Not Include All the Information Needed to Use LONSURF Safely and Effectively
    LONSURF- trifluridine and tipiracil tablet, film coated Taiho Pharmaceutical Co., Ltd. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LONSURF safely and effectively. See full prescribing information for LONSURF. LONSURF (trifluridine and tipiracil) tablets, for oral use Initial U.S. Approval: 2015 RECENT MAJOR CHANGES Indications and Usage (1.2) 2/2019 Recommended Dosage (2.1) 2/2019 Warnings and Precaution (5.1) 2/2019 INDICATIONS AND USAGE LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of adult patients with: metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. (1.1) metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu- targeted therapy. (1.2) DOSAGE AND ADMINISTRATION Recommended Dosage: 35 mg/m2/dose orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle. (2.1) DOSAGE FORMS AND STRENGTHS Tablets: 15 mg trifluridine/6.14 mg tipiracil (3) 20 mg trifluridine/8.19 mg tipiracil (3) CONTRAINDICATIONS None. (4) WARNINGS AND PRECAUTIONS Severe Myelosuppression: Obtain complete blood counts prior to and on Day 15 of each cycle. Withhold and resume at next lower LONSURF dosage as recommended. (2.1, 5.1) Embryo-Fetal Toxicity: Can cause fetal harm.
    [Show full text]
  • Aqueous Immiscible Layered Double Hydroxides – AIM-Ldhs Kanittika Ruengkajorn, Christopher M
    Electronic Supplementary Material (ESI) for Materials Chemistry Frontiers. This journal is © the Partner Organisations 2018 Aqueous Immiscible Layered Double Hydroxides – AIM-LDHs Kanittika Ruengkajorn, Christopher M. R. Wright. Nicholas H. Rees, Jean-Charles Buffet and Dermot O’Hare* Chemistry Research Laboratory, University of Oxford, 12 Mansfield Road, OX3 1TA, Oxford. E-mail: [email protected] Table of contents 1. General experimental details S2 1.1. Analytical techniques for LDH characterisation S2 1.2. Synthesis of Conventional, AMO- and AIM-LDHs S4 2. Supplementary experimental data S6 2.1 Figures S6 2.2 Tables S36 3 References S47 S1 1. General experimental details 1.1 Analytical techniques for LDH characterisation 1.1.1. X-ray powder diffraction (XRD) X-ray powder diffraction (XRD) results were investigated by using a PANalytical X’Pert Pro diffractometer in reflection mode operating at a voltage of 40 kV and a current intensity of 40 mA with Cu-Kα radiation (λ = 1.5406 Å). LDHs and LDOs powder were placed into stainless steel sample holders. A 1° slit was used. Bragg reflections due to sample holder were observed at 2θ = 43-44° and 50° and from silicon wafer were located at 2θ = 33°, 62° and 69°. The Scherrer’s equation was used to estimate the mean crystallite domain length (CDL) of the LDHs; CDL = Kλ(βcosθ)-1, where CDL = the mean crystallite domain length, K = Scherrer constant, λ = the wavelength of the radiation, and β = the full-width at half-maximum height (FWHM) values of a reflection located at 2θ. Thus, the CDL along c- axis (CDL003) can be calculated from the full-width at half-maximum height values of the (003) Bragg reflection, which is assumed to be the total crystal thickness along the c-axis.
    [Show full text]
  • Ep 1559711 A1
    Europäisches Patentamt *EP001559711A1* (19) European Patent Office Office européen des brevets (11) EP 1 559 711 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07D 239/36, C07D 239/40, 03.08.2005 Bulletin 2005/31 C07D 239/42, C07D 213/08, C07D 213/22, C07D 213/16, (21) Application number: 05002053.6 C07D 213/84, C07D 213/85, (22) Date of filing: 01.02.2005 C07D 213/26, C07D 213/65, C07D 213/61 (84) Designated Contracting States: • Zhang, Chang Shan Sankio Chemical Co.,Ltd. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Hiratsuka-shi Kanagawa 254-0016 (JP) HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR • Saitoh, Hiromitsu Sankio Chemical Co.,Ltd. Designated Extension States: Hiratsuka-shi Kanagawa 254-0016 (JP) AL BA HR LV MK YU • Sonoda, Takayuki Sankio Chemical Co.,Ltd. Hiratsuka-shi Kanagawa 254-0016 (JP) (30) Priority: 02.02.2004 JP 2004025806 (74) Representative: Grünecker, Kinkeldey, (71) Applicant: Sankio Chemical Co., Ltd. Stockmair & Schwanhäusser Anwaltssozietät Chuo-ku, Tokyo 104-0031 (JP) Maximilianstrasse 58 80538 München (DE) (72) Inventors: • Kuwabara, Hirokazu Sankio Chemical Co.,Ltd. Hiratsuka-shi Kanagawa 254-0016 (JP) (54) PREPARATION OF PYRIDINE DERIVATIVES USING PYRIMIDINIUM DERIVATIVES AS INTERMEDIATES (57) A method in which a pyridinium derivative of formula (I) such as 1,3-dimethyl-2,3-dihydro-2-oxopyrimidinium chloride is reacted with an acetyl compound of formula (II) such as 4-acetylpyridine, and then the reaction product is reacted with ammonia or an ammonium salt to form a pyridine derivative of formula (III): Also disclosed is a method for the preparation of the compound of formula (I) from reacting a compound of formula (IV) or (V) with a compound of formula (VI): EP 1 559 711 A1 Printed by Jouve, 75001 PARIS (FR) (Cont.
    [Show full text]
  • Justification Document for the Selection of a Corap Substance
    JUSTIFICATION DOCUMENT FOR THE SELECTION OF A CORAP SUBSTANCE ________________________________________________________________ Justification Document for the Selection of a CoRAP Substance Substance Name (public name): Diethyl Ether EC Number: 200-467-2 CAS Number: 60-29-7 Authority: France Date: 21/03/2017 Cover Note This document has been prepared by the evaluating Member State given in the CoRAP update. JUSTIFICATION DOCUMENT FOR THE SELECTION OF A CORAP SUBSTANCE _______________________________________________________________ Table of Contents 1 IDENTITY OF THE SUBSTANCE 3 1.1 Other identifiers of the substance 3 2 OVERVIEW OF OTHER PROCESSES / EU LEGISLATION 5 3 HAZARD INFORMATION (INCLUDING CLASSIFICATION) 7 3.1 Classification 7 3.1.1 Harmonised Classification in Annex VI of the CLP 7 3.1.2 Self classification 7 3.1.3 Proposal for Harmonised Classification in Annex VI of the CLP 7 4 INFORMATION ON (AGGREGATED) TONNAGE AND USES 8 4.1 Tonnage and registration status 8 4.2 Overview of uses 8 5. JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP SUBSTANCE 10 5.1. Legal basis for the proposal 10 5.2. Selection criteria met (why the substance qualifies for being in CoRAP) 10 5.3 Initial grounds for concern to be clarified under Substance Evaluation 10 5.4 Preliminary indication of information that may need to be requested to clarify the concern 11 5.5 Potential follow-up and link to risk management 11 EC no 200-467-2 MSCA - France Page 2 of 11 JUSTIFICATION DOCUMENT FOR THE SELECTION OF A CORAP SUBSTANCE _______________________________________________________________
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,871,970 B2 Inoue (45) Date of Patent: Oct
    USOO887 1970B2 (12) United States Patent (10) Patent No.: US 8,871,970 B2 Inoue (45) Date of Patent: Oct. 28, 2014 (54) PROCESS FOR PRODUCING Andrianarison et al., Journal of Organometallic Chemistry (1990), ORGANOLITHIUM COMPOUND AND 381(2), C38-C42.* PROCESS FOR PRODUCING SUBSTITUTED Colter et al., “Development and Application of a Direct Vinyl Lithia AROMATIC COMPOUND tion of cis-Stilbene and a Directed Vinyl Lithiation of an Unsym metrical cis-Stilbene.” Organic Letters, 2007, 9(8): 1493-1496. (75) Inventor: Hiroki Inoue, Takaoka (JP) Sommer et al., “Synthesis of Aryllithium Compounds in a CYTOS(R) Lab System.” Chemfiles, 2005, 5(7):12-13. (73) Assignee: Nippon Soda Co., Ltd., Tokyo (JP) Thurner et al., “N.N.N',N',N'-Pentamethyldipropylenetriamine (PMDPTA): A Versatile Auxiliary for Site Selected Lithiation Reac (*) Notice: Subject to any disclaimer, the term of this tions, Synthetic Communiations, 1988, 28(3):443-449. patent is extended or adjusted under 35 Wu et al., "Stabilizing N-tosyl-2-lithioindiles with bis(N,N'- U.S.C. 154(b) by 723 days. dimethylaminoethyl)ether-a non-cryogenic procedure for lithiation of N-tosylindoles and subsequent addition to ketones.” Tetrahedron (21) Appl. No.: 12/998,715 Letters, Oct. 7, 2009, 50(40):5667-5669. Wang et al., “Noncryogenic I/Br—Mg Exchange of Aromatic Halides Bearing Sensitive Functional Groups. Using i-PrMgCI (22) PCT Filed: Dec. 25, 2009 Bis2-(N,N-dimethylamino)ethyl Ether Complexes.” Organic Let (86). PCT No.: PCT/UP2009/007286 ters, 2006, 8(2):305-307. Cotter et al., “Development and Application of a Direct Vinyl Lithia S371 (c)(1), tion of cis-Stilbene and a Directed Vinyl Lithiation of an Unsym (2), (4) Date: May 24, 2011 metrical cis-Stilbene.” Organic Letters, 2007, 9(8): 1493-1496.
    [Show full text]
  • 12.27 Nine-Membered Rings
    12.27 Nine-Membered Rings D. O. Tymoshenko AMRI, Albany, NY, USA ª 2008 Elsevier Ltd. All rights reserved. 12.27.1 Introduction 2 12.27.1.1 Scope of the Chapter 2 12.27.1.2 Structural Types 3 12.27.2 Theoretical Methods 3 12.27.2.1 Ab Initio and Semi-Empirical Methods 3 12.27.2.2 Molecular Mechanics 5 12.27.3 Experimental Structural Methods 6 12.27.3.1 X-Ray Crystallography 6 12.27.3.2 NMR Spectroscopy 10 12.27.3.3 Mass Spectrometry 12 12.27.3.4 UV Spectroscopy 13 12.27.3.5 IR and Raman Spectroscopy 14 12.27.3.6 Other Spectroscopic Methods 14 12.27.4 Thermodynamic Aspects 14 12.27.4.1 Intermolecular Forces 14 12.27.4.2 Protonation, Basicity, and Complexation 14 12.27.4.3 Conformational Studies 15 12.27.4.4 Kinetics 16 12.27.5 Reactivity of Nonconjugated Rings 16 12.27.5.1 Intramolecular Thermal and Photochemical Reactions 16 12.27.5.2 Electrophilic Attack on Ring Heteroatoms 17 12.27.5.2.1 Electrophilic attack on ring nitrogen 17 12.27.5.2.2 Electrophilic attack on ring sulfur 20 12.27.5.3 Electrophilic Attack on Ring Carbon 21 12.27.5.4 Reactions with Nucleophiles 21 12.27.5.5 Oxidation and Reduction 22 12.27.5.5.1 Reactions at surfaces 22 12.27.5.5.2 Chemical reduction 23 12.27.5.5.3 Oxidations and oxidation/reduction sequences 23 12.27.5.6 Intramolecular Ring-Transformation Reactions 24 12.27.5.6.1 Ring contractions 25 12.27.5.6.2 Formation of bridged systems and ring expansions 25 12.27.5.6.3 Transannular transformations 27 12.27.5.7 Reactivity of Transition Metal Complexes 28 12.27.6 Reactivity of Substituents Attached to Ring Carbon
    [Show full text]
  • GRAS Notice 695, Dimethyl Ether
    GRAS Notice (GRN) No. 695 http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/default.htm Callaghan Sl ~ TECHNOLOGY..,u CESS March 17, 2017 Dr. Paulette Gaynor Office of Food Additive Safety (FHS-200) MAR 2 0 2017 Center for Food Safety and Applied Nutrition Food and Drug Administration OFFICE OF FOOD ADDITIVE SAFETY 5100 Campus Drive College Park, MD 20740 Re: GRAS Notice for Dimethyl Ether Dear Dr. Gaynor In accordance with 21 CFR §170 Subpart E consisting of §170.203 through 170.285, Callaghan Innovation hereby informs the United States Food and Drug Administration of the conclusion that the intended use of dimethyl ether as an extraction solvent in the processing of various food products is Generally Recognized as Safe (GRAS) as described in the enclosed notice, and thereby the intended use of dimethyl ether is not subject to the premarket approval requirements of the Federal Food, Drug, and Cosmetic Act. I hereby certify that the enclosed electronic files were scanned for viruses prior to submission and are thus certified as being virus-free using McAfee VirusScan 8.8. Should you have any questions or concerns regarding this GRAS Notice, please do not hesitate to contact me at any point during the review process so that we may provide a response in a timely manner. Yours sincerely (b) (6) Stephen Tallon, Ph.D. Senior Research Engineer Callaghan Innovation GRAS Notice for the Use of Dimethyl Ether as an Extraction Solvent Prepared for: Office of Food Additive Safety (FHS-200) Center for Food Safety and Applied Nutrition Food and Drug Administration 5100 Campus Drive College Park, MD 20740 Submitted by: Callaghan Innovation 69 Gracefield Road Lower Hutt 5040 New Zealand March 7, 2017 GRAS Notice for the Use of Dimethyl Ether as an Extraction Solvent Table of Contents Page Part 1.
    [Show full text]
  • Hydrophobic Chitosan Derivatives for Liposome Modification O.O
    Hydrophobic chitosan derivatives for liposome modification O.O. Koloskova, U.A. Budanova, Yu.L. Sebyakin Moscow/Russia Moscow state university of fine chemical technology named after M.V. Lomonosov, prospekt Vernadskogo 86, 119571, Moscow [email protected] Chitosan is an abundant natural polysaccharide with huge availability and potential for biomedical applications due to its biocompatibility, biodegradability, and bioactivity, but its utilization in pharmaceutical formulations has been greatly limited by its intractability. Owing to its semicrystalline nature and multiple H-bond forming groups, chitosan is insoluble in water (when pH > 6.2) and all common organic solvents. Therefore, many works are dedicated to synthesis of new chitosan derivatives to improve its properties for the applications. For example, chitosan is an attractive polymer for liposome modification to obtain a steric stabilized particles. In this work we synthesized a chitosan derivative with residue of palmitic acid as a hydrophobic anchor (which will penetrate into liposomal bilayer and fixate chitosan on the surface). The reaction was carried out in the presence of EDC in the mixture of acetonitrile and a low-concentration solution of acetic acid. The product was purified by washing with non-polar solvents. The structure of the target compound was confirmed by 1H- NMR spectroscopy. As a result, the derivative of chitosan have been synthesized and it can be used to create a steric barrier on the surface of liposomes. This work was supported by the Russian Foundation for Basic Research (grant № 13- 04-00841). Photocatalysis with Visible Light – a Sustainable Application for the Falling Film Microreactor Rehm, T. H.
    [Show full text]
  • 3. Manuscripts
    Novel Benzindoloazecines and Dibenzazecines - Synthesis and Affinities for the Dopamine Receptors Dissertation zur Erlangen des akademischen Grades Doctor rerum naturalium (Dr. rer. nat.) Vorgelegt dem Rat der Biologisch-Pharmazeutischen Fakultät der Friedrich-Schiller-Universität Jena von Dina Robaa geboren am 17. Oktober 1978 in Alexandria 1. Gutachter: Prof. Dr. Jochen Lehmann, Jena 2. Gutachter: Prof. Dr. Gerhard Scriba, Jena 3. Gutachter: Prof. Dr. Peter Gmeiner, Erlangen Tag der öffentlichen Verteidigung: 5. Mai 2011 I Table of contents 1. Introduction ................................................................................................................... 1 1.1. Receptor structure ....................................................................................................... 3 1.2. Tissue distribution ....................................................................................................... 4 1.3. Signal transduction ..................................................................................................... 6 1.4. Functions of the dopamine receptors and their therapeutic implications ............... 7 1.4.1. Control of locomotion and application in movement disorders ..................................... 7 1.4.2. Role in reward and reward-seeking behavior and clinical implication in drug abuse and addictive disorders ............................................................................. 8 1.4.3. Role in psychosis and schizophrenia ......... ..............................................................
    [Show full text]
  • [Product Monograph Template
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrLONSURF® trifluridine and tipiracil tablet 15 mg trifluridine/ 6.14 mg tipiracil (as tipiracil hydrochloride) 20 mg trifluridine / 8.19 mg tipiracil (as tipiracil hydrochloride) Antineoplastic Agent Thymidine phosphorylase inhibitor/nucleoside metabolic inhibitor Taiho Pharma Canada, Inc. Date of Initial Approval: 2010 Winston Park Drive, Suite 503 January 23, 2018 Oakville, Ontario L6H 5R7 Date of Revision: Canada November 18, 2019 Submission Control No: 227070 Page 1 of 40 RECENT MAJOR LABEL CHANGES INDICATIONS (1) 11-2019 WARNINGS AND PRECAUTIONS (6), Geriatrics (6.1.4) 11-2019 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ........................................................................... 2 TABLE OF CONTENTS ................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................... 4 1 INDICATIONS ..................................................................................................... 4 1.1 Pediatrics .................................................................................................... 4 1.2 Geriatrics .................................................................................................... 4 2 CONTRAINDICATIONS ...................................................................................... 4 3 DOSAGE AND ADMINISTRATION .................................................................... 4 3.1 Dosing Considerations...............................................................................
    [Show full text]